To summarize recent findings related to the pathogenic mechanisms of aspirin-induced asthma with emphasis on molecular genetic mechanisms.
15-HETE
Introduction Aspirin (acetyl salicylic acid; ASA) and other nonsteroidal antiinflammatory agents (NSAIDs) cause bronchoconstriction in 10-20% of adults with asthma [1, 2] . This clinical syndrome has been termed ASA-induced asthma (AIA). AIA is commonly found in nonatopic, middle-aged females and is characterized by a typical constellation of symptoms, including moderate to severe asthma, intense eosinophilic inflammation of nasal and bronchial tissues, and higher prevalence of chronic rhinosinusitis and nasal polyposis [3] . The diagnosis of AIA can be established with certainty by challenge tests with increasing doses of ASA. There are four types of challenge tests, depending on the route of ASA administration: oral, bronchial, nasal and, rarely, intravenous tests. Both the oral and the bronchial tests have similar specificity, but the oral test has somewhat higher sensitivity [4] . To avoid the possibility of a severe reaction to an oral ASA challenge, the lysine-ASA bronchoprovocation test is widely used in European and Asian countries. As an in-vitro test, the measurement of ASA-induced 15-hydroxyeicosatetranoic acid (15-HETE) in peripheral blood was suggested as a specific test for the identification of ASAsensitive patients (ASPI test) [5 ] . Most major pathogenic studies of AIA have focused on altered eicosanoid metabolisms. After the European network on AIA reported the occurrence of familial ASA hypersensitivity in 5.1% of the patients in their large survey [6] , the number of molecular genetic studies conducted to identify genetic markers for the susceptibility to AIA has increased. Despite these efforts, the pathogenecity of AIA is still not fully understood.
Cellular and biochemical mechanisms of aspirin-induced asthma
Persistent airway inflammation with intense eosinophil infiltration and the evidence of Cys-LT overproduction are characteristic findings of AIA, and many studies have been attempting to explore cellular and biochemical mechanisms.
Overproduction of cysteinyl leukotrienes and increased expression of cysteinyl leukotriene receptor 1 ASA/NSAIDs block the cyclooxygenase pathway, causing arachidonate substrates to be diverted to the 5-lipoxygenase (ALOX5, or 5-LO) pathway. In this pathway, arachidonate, liberated from membrane phospholipids by cell activation, is converted to the leukotriene LTA4 by ALOX5 and its cofactor 5-lipoxygenase activating protein (ALOX5AP or FLAP). The products of this pathway can induce chemotaxis of inflammatory cells via LTB4 and cysteinyl leukotrienes (Cys-LTs, LTC4/D4/E4). The underlying profound actions of these Cys-LTs include bronchoconstriction, vascular permeability, elevated mucus secretion, eosinophil recruitment, smooth muscle hypertrophy, and fibrous collagen depositions [7, 8] . LTC4 synthase (LTC4S) is the terminal enzyme in the production of Cys-LT and is markedly overexpressed in eosinophils and mast cells of the airway mucosa of AIA patients [9] . Bronchial biopsies from AIA patients revealed a fourfold increase in eosinophils in comparison with the level in ASA-tolerant asthma (ATA) patients, and the baseline concentrations of Cys-LTs measured in the bronchoalveolar lavage (BAL) fluid of AIA patients correlated well with the counts of LTC4S-positive cells in the bronchial mucosa [9, 10] . AIA patients were more sensitive to inhaled Cys-LTs. Cys-LTs are also released into the nasal cavity after nasal challenge with ASA [11] and into bronchi after challenge with lysine-ASA [12] . Most patients with AIA excrete between two and tenfold higher amounts of LTE 4 in their urine than do patients with ATA [13] . Therefore, Cys-LTs have emerged as major mediators in AIA pathogenesis.
The biological activities of Cys-LTs are exerted as consequences of binding to their receptors, CYSLTR1 and CYSLTR2, on surfaces of inflammatory cells [14, 15] . Recent novel studies have demonstrated that the number of cells expressing CYSLTR1 in the nasal mucosa was significantly higher in AIA patients than in ASA-tolerant patients, suggesting that an enhanced response of inflammatory cells to Cys-LTs due to the overexpression of CYSLTR1 may contribute to the pathogenesis of ASA hypersensitivity [16] . They also suggested the effects of Cys-LTs on glands and epithelium may be mediated through CYSLTR2 due to differential distribution between CYSLTR1 and CYSLTR2 in the nasal mucosa [17 ] . Thus, a clue to the underlying anomaly in ASA intolerance can be provided by studying the overproduction of Cys-LTs and the increased expression of CYSLTR1 and CYSLTR2.
Dysregulation of cyclooxygenase and prostaglandins
The cyclooxygenase enzyme, which is central to the mechanism of aspirin intolerance, exists in at least two isoforms, COX-1 and COX-2, which are encoded by distinct genes. ASA and most NSAIDs inhibit both enzymes, but are much more potent inhibitors of COX-1 than COX-2. Specific COX-2 inhibitors can be tolerated by AIA patients. The overall expression of COX-1 and COX-2 was similar in bronchial biopsies obtained from AIA and ATA patients [18] [19] [20] [21] . The two enzymes were coexpressed in the same cell types, that is, bronchial epithelia, smooth muscle cells and fibroblasts; however, their proportions could differ greatly [22] . One major difference identified in cyclooxygenase expression was the downregulation of COX-2 expression in the nasal polyp tissue of AIA patients, suggesting COX-2 dysregulation in AIA [23] .
The inhalation of the prostaglandin PGE 2 could inhibit ASA-induced bronchoconstriction and reduced the LTE4 level in the urine of AIA patients [24] . The basal PGE 2 production by nasal epithelial cells was lower in AIA patients, and this difference was obvious after exposure to ASA, suggesting that the nasal polyp epithelium from AIA patients demonstrates an intrinsic defect in its capacity to generate PGE 2 [25] . A lower production of PGE 2 was also noted in the peripheral blood cells [26, 27] and cultured bronchial fibroblasts of ASA-intolerant rhinitis patients [28] . Moreover, lower PGE 2 production in airway smooth muscle cells was accompanied by the simultaneous downregulation of COX-2 mRNA expression [29] . These findings suggest that NSAIDs may enhance the depletion of this protective prostaglandin, PGE 2 , in association with the downregulation of COX-2.
Inflammatory cells are more activated in aspirin-induced asthma Eosinophil infiltration of upper and lower airway tissue is a central feature of AIA. An elevated serum interleukin (IL)-5 level [30] and an enhanced local production of IL-5 and granulocyte-macrophage colony-stimulating factor were shown in the bronchial mucosa of AIA patients [30, 31] . Increased numbers of mast cells as well as eosinophils were found in the bronchial mucosa of AIA patients [32, 33] . The PGD 2 concentration in AIA patients was significantly higher than in ATA patients [34] . When a segmental bronchial challenge with ASA was performed in AIA and ATA patients [12] , ASA significantly depressed PGE 2 and thromboxane B 2 levels in the BAL fluids of both groups; however, the levels of PGD 2 , PGF 2 a and 9a, 11a-PGF 2 decreased only in ATA patients. Modest increases were seen in the urinary levels of 9a, 11a-PGF 2 and PGD metabolites in AIA patients, suggesting the involvement of activated mast cells as well as eosinophils.
The 15-lipoxygenase pathway: 15-hydroxyeicosatetranoic acid and lipoxin It was reported that the production of 15-HETE by peripheral blood leukocytes in AIA patients is 3.6-fold higher than in ATA patients and that 15-HETE production is enhanced in AIA patients after ASA exposure [35] . Among the potent proinflamatory activities of 15-HETE are the stimulation of proinflammatory mediators from mast cells [36] , the induction of mucous glycoprotein secretion by human airway [37] , and the contraction of human bronchial smooth muscle [18] . 15-HETE, however, also has antiinflammatory activities, including the inhibition of 5-LO activity, the generation of LTB4 in leukocytes [19, 20] , and the production of lipoxin which inhibits eosinophil chemotaxis [21] . The mechanisms by which ASA induces 15-HETE production and the consequent clinical course are not understood.
Lipoxins, antiinflammatory derivatives of arachidonic acid, are derived from the 15-LO pathway and behave as functional antagonists of leukotrienes [38] . Lipoxin production was decreased in AIA patients compared with that in ATA patients [39] . The increased action of Cys-LTs in patients with AIA might be attributable to a diminished capacity for lipoxin synthesis [38, 39] , a possible factor contributing to the clinical course of AIA [21] .
Genetic mechanism of aspirin-induced asthma
To explore the genetic determinants of AIA, association studies of candidate genes, of leukotriene-related genes, in particular, have been undertaken. Most studies have been focused on promoter polymorphisms and nonsynonymous single nucleotide polymorphisms (SNPs).
Leukotriene C4 synthase gene
Two promoter polymorphisms in the LTC4S gene (À1072G>A, À444A>C) were identified, of which LTC4S-444A>C was associated with the AIA phenotype in a Polish population [40, 41] . The homozygous LTC4S-444A allele was associated with a greater increase in urinary LTE4 after an ASA challenge in a Japanese population [42] , and this genetic variation had an additional responsive element for histone H4 transcription factor-2, which increased the in-vivo and invitro transcription rate of LTC4S. This has not been replicated in other populations, however, including US, Japanese, and Korean populations [42, 43, 44 ].
The 5-lipoxygenase gene and leukotriene-related genes
In et al. [45] identified a 5-LO (ALOX5) gene promoter polymorphism, which consisted of a variable number of tandem repeats of GC-rich motifs in association with binding sites for Sp1 transcription factor; individuals with the wild genotype containing five repeats had a significantly higher capacity to produce Cys-LTs than did those with the mutant genotypes containing three, four, or six repeats. This polymorphism was found to be associated with the severity of airway hyperresponsiveness in a Korean population [46] ; AIA patients carrying a mutant allele containing less than or greater than five repeats showed increased airway hyperresponsiveness compared with those with the wild genotype. In addition, AIA patients were screened for 10 SNPs in key enzymes involved in arachidonate metabolism: 5-lipoxygenase (ALOX5; À1708G>A, 21C>T, 270G>A, 1728G>A), 5-lipoxygenase activating protein (ALOX5AP; 218A> G), cyclooxygenase 2 (COX-2; À162C>G, 10T>G, 228G>A), leukotriene C4 synthase (LTC4S; À444A> C), and cysteinyl leukotriene receptor 1 (CYSLTR1; 927T>C). Based on the Korean population, a possible involvement of ALOX5-ht1 [G-C-G-A] in AIA patients was suggested; the frequency of the [G-C-G-A] haplotype of ALOX5 was significantly higher in AIA patients than in ATA. A lack of association was noted between ALOX5AP, COX-2, and CYSLTR1 gene polymorphisms and AIA phenotype [44 ] .
Cysteinyl leukotriene receptor genes
Cys-LTs exert their biological actions by binding to two types of receptors -CYSLTR1 and CYSLTR2. Three SNPs in the 5 0 upstream region of the CYSLTR1 gene (À634C>T, À475A>C, À336A>G) were identified [47] . Male AIA patients had higher frequencies of the minor alleles of these three SNPs than did males in the control group, while no differences were noted in the female patients. A functional study using two cell lines, human T-lymphocyte cell (jurkat) and lung epithelial cell (A549), demonstrated enhanced promoter activity with the ht2 [T-C-G] construct compared with that of the ht1 [C-A-A] construct, suggesting that this polymorphism could modulate CYSLTR1 expression to increase AIA susceptibility. Four SNPs were identified in the CYSLTR2 gene, c.À819T>G, c.2078C>T, c.2534A>G, and c.2545þ297A>G, from a Korean population [48 ] . In that study, the frequencies of rare alleles for c.À819T>G, c.2078C>T, and c.2534A>G were higher in AIA patients than in ATA patients. The patients with rare alleles for c.À819T>G, c.2078C>T or c.2534A>G exhibited a more pronounced fall in forced expiratory volume in 1 s (FEV1) after ASA provocation.
Cyclooxygenase-2 pathway: cyclooxygenase, prostaglandin E2 and thromboxan A2 receptor gene A case-control study of 63 candidate genes was conducted in a Japanese population [49 ] . A functional SNP of PGE 2 receptor subtype 2 (EP2) gene was associated with AIA by reducing the braking effect of PGE 2 on inflammation. A novel promoter polymorphism (À765G>C) of COX-2 has been recently identified in a Polish population [50 ] . The promoter polymorphism of COX-2 showed a significant association with sex, atopy, and an increased PGE 2 production in AIA patients.
The thromboxane A2 receptor (TBXA2R) is a receptor for a potent bronchoconstrictor, TBXA2. The TBXA2R þ795T>C polymorphism may increase bronchoconstrictive response to ASA, which could contribute to the development of the AIA phenotype in the Korean population [51 ] . Increased production of Cys-LTs in AIA patients can be explained by a mechanism via inhibition of ongoing formation of platelet-derived TBXA2 [52] . That study indicated that oral aspirin administration can lead to the uncoupling of the TBXA2-dependent negative feedback mechanism, which may increase the production of Cys-LTs. The TBXA2-dependent regulation of LTC4S activity may be an important pathophysiological mechanism in AIA.
T-box expressed in T cells gene
The gene TBX21 encodes the transcription factor T-bet, which is T-box expressed in T cells. It influences naive T-lymphocyte development and has been implicated in asthma pathogenesis [53] . The À1993T T>C polymorphism in the TBX21 promoter was associated with an increased risk for AIA in a Japanese population by increasing transcriptional activity [54 ] . This genetic variation can cause inappropriate Th1 cell responses in the airway, leading to severe airway inflammation, suggesting that the Th1 cell response may play a role as great as that of the Th2 cell response in the pathogenesis of AIA. It was cautiously proposed that AIA may be classified roughly as Th1/Th2 mixed-type asthma.
HLA allele
The association of HLA DPB1
Ã 0301 with AIA has been reported in a Polish population [55] . The increased frequency of DPB1 Ã 0301 in AIA patients compared with that in normal controls and in controls with asthma suggests that immune recognition of an unknown antigen may be part of the pathogenesis of AIA. These findings were replicated in a Korean population [56 ] . The patients with DPB1
Ã 0301 tended to be female, have lower FEV1, and show higher prevalence of rhinosinusitis or nasal polyp in comparison with patients without the allele. Furthermore, the presence of HLA DPB1
Ã 0301 was significantly associated with the requirement for leukotriene receptor antagonists in the long-term management of AIA patients [57 ] .
Interaction between the candidate genes
Recent investigations have suggested gene-gene interaction or epigenetic regulation in the pathogenic mechanism of AIA. The genetic effects of CYSLTR2 c.2078C>T (or CYSLTR2 c.2534A>G) and LTC4S-444A>C synergistically increased the decrease in FEV1 after lysine-ASA inhalation, which strongly suggests that interactions between CYSLTR2 and LTC4S may cooperatively influence the development of ASA intolerance in patients with asthma [48 ] . The TBXA2R þ795T>C polymorphism was significantly associated with the presence of HLA DPB1
Ã 0301 in AIA patients compared with ATA patients [51] . The TBXA2R þ924T>C polymorphism had no association with AIA, but the frequency of the mutant genotype combination of TBXA2R þ924T>C and ALOX5þ 21C>T was significantly higher in AIA patients than in ATA patients or in normal controls. This result suggests that a gene-gene interaction of TBXA2R and ALOX5 may be synergistically associated with the AIA phenotype. Further investigations are needed to determine how genes interact in the pathogenesis of AIA.
Conclusion
Further information on the genetic polymorphisms of candidate AIA-related genes along with supporting functional studies will help to elucidate the molecular mechanisms of AIA and may lead to the development of new diagnostic markers and additional therapeutic targets based on genetic information.
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